Therapeutic effect and influence of fluvastatin combined arotinolol on GDF-15 and NGAL levels in patients with coronary heart disease complicated heart failure / 心血管康复医学杂志

ABSTRACT

Objective: To study therapeutic effect and influence of fluvastatin combined arotinolol on serum levels of growth differentiation factor 15 (GDF-15) and neutrophil gelatinase associated lipocalin (NGAL) in patients with coronary heart disease (CHD) complicated heart failure (HF). Methods: A total of 140 CHD + HF patients, who were treated in our department of cardiology from May 2013 to May 2015, were selected. According to random number table, patients were randomly and equally divided into arotinolol group and combined treatment group (received fluvastatin based on arotinolol group), both groups were treated for three months. Therapeutic effect, left ventricular end-diastolic dimension (LVEDd), end-diastolic interventricular septal thickness (IVSTd), left ventricular ejection fraction (LVEF), mean arterial pressure (MAP), cardiac index (CI), stroke index (SI), stroke volume (SV), serum levels of GDF-15 and NGAL before and after treatment were compared between two groups. Results: Compared with arotinolol group after treatment, there were significant rise in LVEF [(45. 31±6. 73) ％ vs. (72. 64±7. 29) ％], MAP [(59. 34±6. 93) mmHg vs. (75. 61±7. 24) mmHg], CI [(2. 66±1. 31) L/min2 vs. (3. 12± 1. 37) L/min2], SI [(27. 15±4. 37) ml/m2 vs. (49. 81±5. 79) ml/m2]and SV [(60. 99±5. 13) ml vs. (71. 24± 5. 94) ml], and significant reductions in IVSTd [(13. 51±3. 17) mm vs. (11. 27±7. 26) mm], serum levels of GDF-15 [(1153. 4±153. 7) ng/L vs. (923. 8±81. 4) ng/L]and NGAL [(112. 52±61. 49) μg/L vs. (78. 14± 35. 74) μg/L]in combined treatment group (P＜0. 05 or＜0. 01). Total effective rate of combined treatment group was significantly higher than that of arotinolol group (87. 14％ vs. 74. 29％), P=0. 007. Conclusion: Fluvastatin combined arotinolol can effectively improve heart function, significantly reduce serum GDF-15 and NGAL levels, and improve prognosis in CHD + HF patients, which is worth extending.